AzTrials
AzTrials

Anesthesia, CaudalPhase 3NCT05133687

The Hemodynamic Effects of Different Volumes of Bupivacaine 0.25% Caudal Blocks in Pediatrics Undergoing Lower Abdominal Surgeries as Measured by Electrical Cardiometry

A Phase 3 study testing Bupivacaine Hydrochloride in people with Anesthesia, Caudal and Pediatrics, run by Kasr El Aini Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized, controlled study is designed to estimate the effects of different volumes of plain bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry. Read more about this study

Who is it for?
Ages 1 year to 8 years
Conditions the study is for
Anesthesia, Caudal, Pediatrics
What is being tested?
Bupivacaine Hydrochloride
Could I receive a placebo?
No, everyone receives an active treatment
How many people
105 participants
Where
1 siteEgypt
Study dates
15 Nov 2021to 30 May 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 8 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • All pediatrics ASA I\&II aged 1-8 years undergoing elective lower abdominal surgeries.

Who cannot join

  • ASA ≥ III. Parents refusal of caudal block. Patients with coagulation disorders (Platelets ≤ 50,000 and/or INR> 1.5). Patients with suspected or proved allergic to local anesthetics. Rash or signs of infection at the injection site. Patients requiring emergency or laparoscopic procedures.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Cairo university hospitals, kasralainy

    Cairo, 11559

Other trials in Egypt

About this study

Official title: The Hemodynamic Effects of Different Volumes of Bupivacaine 0.25% Caudal Blocks in Pediatrics Undergoing Lower Abdominal Surgeries as Measured by Electrical Cardiometry: A Randomized Controlled Study

This randomized, controlled study is designed to estimate the effects of different volumes of plain bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.

Read the detailed description

Introduction:

Caudal block is one of the most used regional blocks in pediatrics because it is safe and provides efficient and adequate perioperative analgesia for most of the infra-umbilical and lower limb procedures.[1,2] It has been proposed that the cardiovascular effects of neuraxial blocks are less marked in children than in adults because of lower systemic vascular resistance (SVR) in pediatric population.[3] There is a wide range of doses used in caudal block depending on the desired dermatomal level which can range from 0.5ml/kg up to 1.25ml/kg. [1] However, studies assessing effects and safety of different volumes of caudal blocks on different hemodynamic variables are scarce and show conflicting results due to small sample sizes, absence of control groups, retrospective nature, different additives and different methods for measuring the hemodynamics.[4-8] Electrical Cardiometry (EC) estimates cardiac parameters by measuring changes in thoracic electrical bioimpedance during the cardiac cycle using skin electrodes. It has emerged as a new noninvasive tool for assessment of cardiac output with a good accuracy in adult and pediatric anesthesia.[9] The current study is designed to estimate the effects of different volumes of bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.

Hypothesis:

We hypothesized that different volumes of plain bupivacaine 0.25% caudal block could have direct effects on different hemodynamic parameters in pediatrics undergoing lower abdominal surgeries.

Methods:

The study is a double blinded randomized controlled trial that will be conducted at Abu Al Reesh Children's Hospital, Faculty of Medicine, Cairo University after approval of research and ethics committees.

Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.

Randomization will be achieved using a computer-generated sequence. Concealment will be achieved using opaque envelopes.

All children will be anesthetized in accordance with the local policy of pediatric anesthesia unit in Abu El-Reesh pediatric hospital-Cairo university.

After preoperative examination and upon arrival to the operating room heart rate HR, noninvasive blood pressure NBP and oxygen saturation SPO2 will be monitored using standard monitor (drȁger infinity vista XL) before inhalational induction of anesthesia using titration of sevoflurane in oxygen air mixture 60% (starting from 3% up to 8%) until the child is put to sleep. Electrical cardiometry device (ICON; Cardiotonic, Osypka; Berlin, Germany) will be applied to the patient through 4 ECG electrodes at the following sites: (forehead, left side of the neck, left mid-axillary line at the level of xiphoid process and left thigh). Patient's sex, height, and weight will be entered into the device, which is set to estimate cardiovascular parameters at a 20-beat moving average recorded every10 seconds. The ECG electrodes will be placed before induction for cooperative children. Baseline electrical cardiometry (ICON) data (Cardiac output, Cardiac index, Stroke volume, Stroke volume variation, Stroke index, Systemic vascular resistance, Systemic vascular resistance index, ICON, VIC, Thoracic fluid index, Left cardiac work, Systolic time ratio, Pre ejection period, Left ventricular ejection time) will be recorded by averaging 3 sets of data over 30 seconds by an anesthesia resident who is blinded to the children groups.

After securing an intravenous line anesthesia will be completed with 1-2µg/kg of fentanyl and atracurium 0.5 mg/kg to facilitate endotracheal intubation. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.

The concealed envelopes will then be opened by a second anesthesia resident (who will not be involved in patient management) and he will be responsible for preparing and giving the caudal block for the caudal groups as instructed in the envelope.

Children in groups (0.8-G) and (1.2-G) will then be positioned on their right side, and a 22-gauge needle will be aseptically inserted into the caudal epidural space. Bupivacaine 0.25% at a dose of 0.8 ml/kg and 1.2 ml/kg making sure not to exceed a maximum of 2.5 mg/kg will be slowly injected. After repositioning the children on their backs, a 10-min steady-state period without surgical stimulation will be permitted during which a multiple set of measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), and surgery will be started after this period. Caudal success will be defined as change of hemodynamics (heart rate and or blood pressure) < 20% of base line parameters to surgical incision without need for additional analgesics or increase of inhalational anesthetics. Patients with caudal failure will be excluded from the study.

In group G the surgery will be started after 10 minutes from the induction of anesthesia where a multiple sets of ICON measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), from the previous baseline measurements.

In all groups ICON measurements will be obtained every 10 minutes after start of surgery till the end of surgery.

In all groups HR, NBP, SPO2 and end tidal CO2 will be measured every 2 minutes for 10 minutes after induction of anesthesia then every 10 minutes till the end of surgery.

All children will receive a loading dose of 10 ml/kg of lactated ringer solution over 10 minutes after induction of anesthesia and will be maintained on 3 ml/kg/h lactated ringer solution.

Being tested
Bupivacaine Hydrochloride
Keywords
pediatrics, caudal anesthesia, hemodynamics, electrical cardiometry, bupivacaine 0.25%

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine HydrochlorideDrug

    Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).

Study groups in NCT05133687
Study groupRoleWhat they receive
Group (0.8-G)ExperimentalThis group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25%
Receives: Drug: Bupivacaine Hydrochloride
Group (1.2-G)ExperimentalThis group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25%
Receives: Drug: Bupivacaine Hydrochloride
Group GActive comparatorThis group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
Receives: Drug: Bupivacaine Hydrochloride

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The percentage of change from the baseline measurement of the cardiac index CI 10 minutes after successful caudal block.

    Measured: 10 minutes after caudal block.

Secondary outcomes (4)
  1. Electrical cardiometry cardiac index

    Measured: 30 minutes

  2. mean ABP

    Measured: 1-2 hours

  3. Incidence of complications: block failure, bradycardia (HR < 80/min) , hypotension (blood pressure <20% of base line) and local anesthesia systemic toxicity (LAST)

    Measured: 1-2 hours

  4. heart rate

    Measured: 1-2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2021
  2. Study start15 Nov 2021
  3. Primary completion30 May 2022
  4. Study completion30 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Model description
Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
105 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05133687
Sponsor's protocol ID
MS-445-2021
Status last verified
Jul 2024
First submitted
15 Nov 2021
Last updated
9 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Bupivacaine Hydrochloride in people with Anesthesia, Caudal and Pediatrics, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The percentage of change from the baseline measurement of the cardiac index CI 10 minutes after successful caudal block. (time frame: 10 minutes after caudal block.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in